TABLE 1.
Clinical and Pathological Characteristics of Study Population
| Variable | Overall (n = 101) |
|---|---|
| Age, median (IQR), y | 60 (49–68) |
| Sex, male, n | 58 |
| Performance status, n | |
| 0 | 32 |
| 1 | 50 |
| 2 | 19 |
| Functional, n | 5 |
| Somatostatin receptor imaging, n | |
| Negative | 17 |
| Positive | 47 |
| Unknown | 37 |
| Ki-67, median (IQR), % | 50 (20–80) |
| Ki-67, n | |
| <55% | 52 |
| ≥55% | 35 |
| Unknown | 14 |
| Differentiation, n | |
| Well-differentiated (PanNET) | 50 |
| Poorly differentiated (PanNEC) | 29 |
| Unknown differentiation | 22 |
| Grade (PanNET only), n | |
| Grade 1 | 6 |
| Grade 2 | 19 |
| Grade 3 | 25 |
| Stage at presentation, n | |
| III | 5 |
| IV | 96 |
| Best overall response scheme, n (%) | |
| Platinum/Etoposide | 57 |
| Platinum/Irinotecan | 9 |
| Platinum/Gemcitabine | 17 |
| Oxaliplatin/5-FU | 15 |
| Platinum | 3 |
PanNET indicates pancreatic neuroendocrine tumor; PanNEC, pancreatic neuroendocrine carcinoma.